Sibutramine has a dual mode of action. It reduces food intake and attenuates the fall in metabolic rate associated with weight loss. The drug's neurochemical actions can also be distinguished from those of previous centrally acting anti-obesity agents. Clinical trials show that two out of three patients taking sibutramine lose 5% weight and that the drug can enhance the maintenance of weight loss. Early weight loss predicts long-term success and can be used to guide clinical practice. To maximize the benefits of sibutramine, it is important that patients receive adjunctive diet and lifestyle therapy. International Journal of Obesity (2002) 26, Suppl 4, S29 -S33. doi:10.1038/sj.ijo.802216
Sibutramine has a dual physiological action, influencing both sides of the energy balance equation. It reduces food (energy) intake by enhancing satiety (fullness) and it reduces the decline in metabolic rate that occurs with weight loss.
The acute effects of sibutramine on energy intake have been demonstrated in a laboratory setting. 1 In a crossover study in normal-weight adult males, sibutramine significantly decreased the amount of food and the energy content of food that the subjects chose to consume, resulting in a reduction of 312 kcal during the day (P 0.001). In another study, 2 the effect of sibutramine on energy intake was measured after 14 days' treatment. Energy intake was recorded by detailed diet diaries and dietary interviews. At each meal, individuals who had taken sibutramine consumed significantly less food than those who had taken a placebo (P < 0.05) with a reduction in total energy intake of 356 kcal per day.
The psychological constructs, such as hunger or fullness, that lead to eating behaviour can be measured by asking subjects to record them at regular intervals using a visual analogue scale (VAS). These results can be plotted against time and the area under the curve taken as an index of the construct under investigation. In one study, 3 subjects were asked to complete a series of hourly VAS scores from 08:00 to 23:00 h. Compared with placebo, sibutramine was associated with enhanced fullness (not significant) and satiety (P ¼ 0.003), while hunger and expectation (how much the subject thought they could eat) were both significantly reduced (P ¼ 0.003). These findings suggest that sibutramine is not acting as a classical anorectic drug because it does not stop individuals from starting to eat but it enhances and prolongs the feeling of fullness that develops normally after eating. In other studies, this has been shown to result in earlier termination of a meal and the avoidance of inter-meal snacks.
The effect on body weight of this reduced energy intake can be quantified. For example, for a subject weighing 83 kg, total daily energy expenditure can be predicted to be about 3000 kcal. If sibutramine reduces energy intake by 300 -400 kcal a day, over a 6 month period this would lead to a predicted weight loss of around 10 kg. However, sibutramine has a second mechanism of action; its thermogenic effects 4 limit the fall in metabolic rate, and the consequent fall in energy expenditure, that occurs with weight loss. This action produces additional weight loss. These dual actions predict that sibutramine would lead to both weight loss and weight loss maintenance, findings confirmed in clinical trials.
Neurochemical actions of sibutramine
Sibutramine influences both noradrenergic and serotonergic (5HT) pathways within the hypothalamus concerned in energy balance, inhibiting reuptake of both serotonin and noradrenaline released from hypothalamic neurons. Both these effects are integral to its anti-obesity actions. As shown in Table 1 , these neurochemical actions serve to distinguish sibutramine from previous centrally acting antiobesity agents.
The early amphetamine-like drugs -dexamphetamine and phentermine -were potent agents that stimulated the release of dopamine and noradrenaline centrally. The next generation of drugs -the fenfluramines -acted predominantly by stimulating release of serotonin, both centrally and almost certainly peripherally. Continued stimulation led to depletion of presynaptic neurotransmitters and possible neurotoxicity. It is that direct releasing effect, particularly in the periphery, that is likely to have led to the unwanted effects associated with the fenfluramines. With sibutramine, physiological, rather than directly stimulated, release of neurotransmitter occurs but, because reuptake is blocked, the effect of the neurotransmitter on post-synaptic receptors is enhanced. There is no depletion of neurotransmitter in the presynaptic vesicles and this difference is fundamental to an understanding of sibutramine and its different, and improved, safety profile.
Fluoxetine, an anti-depressant, is also a serotonin but not a noradrenaline reuptake inhibitor and has been evaluated as a weight loss agent. While it produced modest short-term weight loss, weight was regained, despite continued administration, and the drug therefore has no proven value for weight management.
Weight loss with sibutramine
Clinicians are interested not just in weight loss, but also in maintenance of weight loss. The ultimate goal of treatment for obese patients is to lose weight and then to maintain the new weight, ie to reach a perfect plateau. However some weight regain with time is probably inevitable. The natural history of body weight is to increase with age, usually at the rate of 1 -2 kg=y. To achieve a complete plateau would require a drug not only to continue exerting its effect, but to exert an ever-increasing effect to counteract the natural course of weight gain. It seems likely that a small degree of weight regain is biologically almost inevitable with any drug, and not a sign of declining efficacy.
The STORM (Sibutramine Trial on Obesity Reduction and Maintenance) trial 5 was designed to evaluate the effects of sibutramine on weight maintenance after an initial period of weight loss. It was a double-blind, randomized, placebocontrolled study conducted over 18 months in patients who had successfully lost weight (> 5%) in a 6 month open-label weight loss phase in which all subjects were given sibutramine (10 mg=day), diet, exercise and behavioural support. The study was conducted in eight European centres and recruited 605 patients with a mean age of 40 y. Around 500 patients completed the weight-loss phase and 467 were randomized (352 sibutramine and 115 placebo) into the 18-month, double-blind, weight-maintenance phase. Overall, 204 subjects completed the sibutramine arm of the study and 57 the placebo arm.
Despite the continued lifestyle programme, patients assigned to placebo began to regain weight 2 months after randomization. Their weight trajectories subsequently clearly separated from the sibutramine group (Figure 1) . The placebo group continued to regain weight steadily and by month 24 had regained nearly 80% of the weight loss achieved during the initial weight-loss phase. In contrast, in the sibutramine group, weight loss was maintained to 18 months (12 months after the weight loss phase) before there was evidence of weight regain. This regain was slight and reflected the normal weight increase that might be expected with time. At month 24, the sibutramine group had maintained over 85% of the weight loss achieved at the end of the weight loss phase. This 2 y study therefore demonstrates that sibutramine not only induces weight loss but is also able to maintain that weight loss in the long term. Figure 2 compares the results of sibutramine treatment in the STORM study against a weight trajectory predicted for untreated obese patients over a 2 y period (2 kg=y). The divergence between the two lines shows the drug's efficacy in long-term weight maintenance.
Adjunctive diet and lifestyle therapy is important to maximize the effects of any drug treatment of obesity. This Figure 1 Weight loss and weight maintenance in the STORM study. Source: James et al. 5 Mode of action and efficacy N Finer can be illustrated by a comparison of four sibutramine clinical trials.
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A 12 month placebo controlled trial conducted in general practice 6 used one of two doses of sibutramine (10 and 15 mg) in combination with simple, written, dietetic advice. Sibutramine was effective but the difference between the 10 mg dose and the placebo group was small (about 4 -5%). Weight loss was maintained throughout the year but the absolute weight loss was relatively limited.
The second trial was a 6 month dose-ranging study conducted in a hospital setting but again with limited dietary intervention. 7 Overall, weight loss with sibutramine was approximately 10 lb (4.5%).
A third trial 8 used 4 weeks of a very-low energy diet (220 -800 kcal=day) for weight loss induction. This resulted in a weight loss of approximately 7 kg. Patients were then randomized to a more modest diet, which was tightly supervised, and individually prescribed, together with sibutramine or placebo for 12 months. In placebo-treated patients, maintenance of the weight lost in the initial 4 weeks was quite good. However, patients in the sibutramine group continued to lose weight and then maintain this further weight loss over the 12-month study period. Total weight loss was significantly greater in the sibutramine group (P < 0.001 compared with placebo).
The hospital-based STORM study 5 provided comprehensive, individual and supervised lifestyle management incorporating both diet and exercise. It showed that extremely good weight loss can be achieved if the drug is given continuously, together with diet and lifestyle advice and support.
Considering these four trials together ( Figure 3) shows clearly that the two trials that provided sibutramine with only minimal diet and lifestyle advice produced modest weight loss, but were not nearly as successful as those providing a more intensive support programme. Thus, to achieve the best results from sibutramine, patients should be treated comprehensively, and the drug must not be used in place of diet and lifestyle advice.
As shown in Table 2 , while there is benefit from any degree of weight loss, there are greater benefits from modest weight loss of 5%, while a weight loss of 10%, if this can be achieved, has been reported to be associated with improvements in sleep apnoea and asthma and decreased mortality. 9 -17 Data collated from six 1 y placebo-controlled studies of sibutramine 18 show that 76% of subjects who received placebo failed to achieve even a 5% weight loss, despite the drug being used in a clinical trial setting. In contrast, twothirds of those who received sibutramine achieved 5% weight loss and a third achieved 10% weight loss (Figure 4) . It is important to remember that analysis of clinical trials requires that all patients entered are retained even if they are early non-responders. In clinical practice, a patient who had failed to respond in the first weeks or months of treatment Figure 2 Weight maintenance in the STORM study compared with expected weight gain over a two-year period. Source: adapted from James et al. Figure 4 Weight loss in sibutramine-treated patients (data taken from six 12 month placebo controlled studies). Source: Astrup et al. 18 Mode of action and efficacy N Finer
would not continue to be treated for a year or more. Mean weight loss and weight maintenance data from trials therefore will tend to underestimate the likely clinical weight loss that might be expected on average in clinical practice.
Predictors of success
Data from the STORM study have been evaluated to see if pretreatment factors can be identified that predict treatment response. 19 Although some factors did predict successful weight loss (eg pre-treatment body weight, resting metabolic rate), these were poor predictors and accounted for less than 10% of the variability between individuals in their response to sibutramine.
Initial weight loss in response to sibutramine treatment, however, is known to be an important predictor of long-term success. 20 Patients who lose between 1 kg and 2 kg at 1 month are predicted to achieve a 3.5 kg weight loss at 1 y while those who lose more than 3 kg at 1 month might be expected to achieve a 10.5 kg weight loss. Patients who do not achieve 3 kg weight loss by 3 months are unlikely to achieve any significantly important weight loss at 1 y (Figures 5 and 6 ). Further analysis of sibutramine trial data suggests that 72% of patients who lost 2 kg at week 4 went on to become 5% responders (Abbott Laboratories, data on file).
In clinical practice, these figures can be used to target treatment to appropriate patients in order to achieve medically valuable weight loss.
Summary
Sibutramine has two modes of action, affecting both energy intake and energy expenditure. Clinical trials show that two-thirds of patients will achieve a weight loss of 5% and one-third a weight loss of 10%. Weight loss is enhanced if intensive lifestyle therapy is also provided. In clinical practice, a patient's response to the first month of treatment is an important predictor of long-term weight loss and maintenance. Mode of action and efficacy N Finer
